Search - tctmd.com

Displaying 1 - 20 of 169

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

L.A. McKeown

February 04, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

L.A. McKeown

June 27, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Caitlin E. Cox

June 25, 2025

News Daily News

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

Caitlin E. Cox

April 17, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

January 2026 Dispatch for the CV Team

JACC Debuts Data Digest on CV Health in the United States

December 2025 Dispatch for the CV Team

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

TCTMD’s Top 10 Most Popular Stories for July 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

March 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Top General Cardiology and Prevention News of 2024

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content